Abstract
The myeloproliferative neoplasms displaying a PDGFRB rearrangement are rare diseases derived from a haematopoietic stem cell. The goals of the study were to assess the incidence of these disorders and to define the clinical and biological characteristics as well as the response to the imatinib therapy. A total of 556 patients with myeloproliferative neoplasms were studied by means of molecular cytogenetics. The incidence of myeloproliferative neoplasms (MPN) with PDGFRB rearrangement was low (10 cases, 1.8% of all MPN). Most of the patients showed moderate anaemia (median Hb was 10.0 gr/dL; range from 7.5 to 13 g/dL), leukocytosis (median white blood cells was 21.7 × 10(9) /L with a range from 4 to 43 × 10(9) /L) and eosinophilia (median circulating eosinophils was 2.4 × 10(9) /L with a range of 1.1-5.7 × 10(9) /L) with a median of bone marrow infiltration cells displaying PDGFRB rearrangement of 55% (range, 37-85%). In three cases, a t(5;12) was observed while two patients showed rearrangements of 17q21 region. In two cases, a del(5)(q31) was observed. Most of the patients responded to standard dosage of imatinib, and the response was maintained in the time in those patients with a follow-up higher than 9 years. The incidence ...Continue Reading
References
Apr 22, 1994·Cell·T R GolubD G Gilliland
Sep 29, 1999·Genes, Chromosomes & Cancer·F YagasakiK Hirashima
Jun 10, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M HernándezJ F San Miguel
Mar 29, 2002·Acta Haematologica·E Joanna Steer, Nicholas C P Cross
Jul 3, 2002·Leukemia·N C P Cross, A Reiter
Aug 16, 2002·The New England Journal of Medicine·Jane F ApperleyJohn M Goldman
Jan 25, 2003·British Journal of Haematology·E Joanna BaxterNicholas C P Cross
Sep 25, 2003·Blood·Juan L GarciaJesus F San Miguel
Mar 24, 2004·Leukemia Research·Animesh Pardanani, Ayalew Tefferi
Dec 8, 2004·Cellular and Molecular Life Sciences : CMLS·A V Jones, N C P Cross
Sep 9, 2006·Blood·Marianna DavidJane F Apperley
Feb 14, 2007·Haematologica·Els Lierman, Jan Cools
Feb 14, 2007·Haematologica·Christoph WalzAndreas Reiter
Feb 20, 2007·Current Drug Targets·Andreas ReiterNicholas C P Cross
Jun 21, 2008·Acta Haematologica·Nicholas C P Cross, Andreas Reiter
Jan 30, 2009·Journal of Cellular and Molecular Medicine·Ayalew Tefferi
May 28, 2009·Cancer·Ayalew TefferiJames W Vardiman
Jan 29, 2010·Haematologica·Philipp ErbenAndreas Reiter
Mar 2, 2010·International Journal of Hematology·Martha Wadleigh, Ayalew Tefferi
Citations
Dec 26, 2015·Experimental Hematology·Takeshi IshibashiNobutaka Kiyokawa
Dec 31, 2015·Leukemia Research Reports·Gillian C Bell, Eric Padron
Mar 20, 2015·Internal Medicine·Naoto Takahashi
May 13, 2014·European Journal of Haematology·Maryam ArefiJuan Luis García
Jun 7, 2014·Blood·Francesco Passamonti
Apr 2, 2014·Blood·Chan Y CheahJohn F Seymour
Sep 30, 2016·Archives of Pathology & Laboratory Medicine·Daniel F Boyer
Oct 22, 2013·São Paulo Medical Journal = Revista Paulista De Medicina·Alex Freire SandesEdgar Gil Rizzatti
Jan 19, 2018·International Journal of Laboratory Hematology·D T LynchK Foucar
Aug 16, 2015·American Journal of Clinical Pathology·Francisco VegaRoberto N Miranda
Jan 7, 2020·Current Opinion in Hematology·Sam SadighGabriela Hobbs
Feb 23, 2020·Histopathology·Hong FangSa A Wang
Feb 27, 2020·Leukemia & Lymphoma·Akihito NagataKazuteru Ohashi
Jan 1, 2014·Terapevticheskiĭ arkhiv·A L MelikianT N Obukhova
Oct 8, 2019·Expert Review of Hematology·Alessandra IurloUmberto Gianelli
Feb 18, 2017·The American Journal of Case Reports·Mirela AndreiJen Chin Wang
Sep 5, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Aaron T GerdsHema Sundar
Jan 5, 2021·Current Opinion in Pediatrics·Yana Pikman, Elliot Stieglitz
Dec 29, 2020·American Journal of Clinical Pathology·Olga PozdnyakovaSa A Wang
Jan 30, 2021·World Journal of Clinical Cases·Shi-Chong Wang, Wen-Yu Yang
Mar 15, 2021·Blood Reviews·Grzegorz Helbig, Amy D Klion
Jul 3, 2021·Cancers·Magda ZanelliStefano Ascani
Feb 7, 2019·Acta Haematologica·Bella BieloraiAmos Toren